Physician profile
Sean Thomas
NPI 1265595243
$3,418.00
in general payments reported to CMS, 2019-2025
23 companies · $642 in 2025
The $642 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $222 · 2021: $292 · 2022: $639 · 2023: $588 · 2024: $417 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.13 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $423.01 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $347.31 | 2019-2025 | Dupixent |
| Abbvie INC. | $340.09 | 2019-2025 | Skyrizi |
| Genzyme Corporation | $315.60 | 2023-2025 | |
| Amgen INC. | $265.36 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $237.62 | 2019-2025 | |
| Celgene Corporation | $215.21 | 2019 | |
| Sun Pharmaceutical Industries INC. | $215.16 | 2020-2025 | |
| Ucb, INC. | $192.63 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $190.88 | 2021-2023 | Tremfya, Simponi, Remicade |
| Incyte Corporation | $123.38 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $105.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $80.24 | 2019-2024 | |
| Epi Health, LLC | $65.23 | 2020-2022 | |
| Almirall LLC | $62.19 | 2022-2025 | Klisyri, Seysara |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $50.16 | 2022-2024 | Vtama |
| Prugen, INC. Pharmaceuticals | $38.89 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $30.69 | 2025 | Sotyktu |
| Vyne Pharmaceuticals INC. | $29.40 | 2021 | |
| Galderma Laboratories, L.P. | $29.33 | 2020-2021 | |
| Nobelpharma America, LLC | $22.10 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $20.86 | 2022 | |
| Mayne Pharma Commercial LLC | $17.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.